奥沙利铂联合卡培他滨治疗晚期大肠癌36例临床观察

The clinical observation of oxaliplatin combined capecitabine for 36 patients with locally advanced or metastatic colorectal cancer

目的:观察奥沙利铂(L-OHP)联合卡培他滨(Capecitabine,希罗达)治疗晚期大肠癌的疗效及毒性反应。方法:收集从2008年2月至2012年5月我院36名采用奥沙利铂联合卡培他滨方案化疗的晚期大肠癌患者的临床资料。入组患者均经病理组织学证实,且有可测量病灶。具体方案为:第1天L-OHP 130 mg/m2,第1～14天希罗达1 250 mg/m2。21 d为1个周期,化疗2个周期后评价疗效及毒性反应。结果:36例入组患者,其中完全缓解(complete response,CR)3例(8.1%),部分缓解(partial response,PR)16例(43.2%),有效率(response rate,RR)为51.3%,稳定(stability rate,SD)13例(35.1%),进展(progressive disease,PD)5例(13.5%)。临床受益率为86.4%,疼痛缓解率83.3%。肿瘤中位进展时间7.2个月,中位生存期13.8个月。主要毒副反应为骨髓抑制、神经系统毒性、手足综合征、消化道反应和肝功能异常,未出现治疗相关性死亡。结论:奥沙利铂联合卡培他滨方案治疗晚期大肠癌患者有较好疗效,毒副反应可以接受。

Objective：To investigate the efficacy and toxicity of oxaliplatin （L-OHP） combined with capecitabine for patients with lo- cally advanced or metastatic eolorectal cancer. Methods： From February 2008 to May 2012,36 evaluable patients with locally ad- vanced or metastatic colorectal cancer received L-OHP（ 130 mg/m2 ） on day 1 and capecitabine （ 1250 mg/m2 ） from day 1 to 14. The regimen was repeated every 3 weeks and efficacy and toxicity were evaluated after 2 cycles. Results： In 36 included patients,3 cases displayed complete response, 16 cases partial response, 13 cases stable disease and 5 cases progressive disease. The response rate of the whole group was 51.3% and the stabihty rate was 46. 7%. The clinical response rate was 83. 3%. Median time .to progression was 7.2 months and median overall survival time was 13.8 months. Dose limiting toxicity was myelosuppression, neurotoxicity, hand-foot syndrome,digestive tract reactions and hepatic dysfunction. There was no death during the treatment. Conclusion： The regimen L- OHP combined with capecitabine is effective and tolerable in locally advanced or metastatic colorectal cancer.